Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

The Association between Circulating Adipocytokine Omentin Levels and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis

Author(s): Rozita Khodashahi, Mohsen Aliakbarian, Gordon A Ferns and Mohammad-Hassan Arjmand*

Volume 24, Issue 11, 2024

Published on: 17 October, 2023

Page: [1374 - 1381] Pages: 8

DOI: 10.2174/1566524023666230913105910

Price: $65

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condition worldwide. NAFLD is often associated with features of Metabolic Syndrome such as obesity and insulin resistance.

Methods: The current comprehensive meta-analysis was performed to evaluate the association between circulating Omentin levels and NAFLD. A systematic search in Scopus, Web of Science, PubMed, and Google Scholar databases was conducted to identify relevant studies up until 5th May 2022. The standard mean difference (SMD) values and 95% confidence intervals (CIs) were computed for the association of Omentin levels with NAFLD risk in a random effect model.

Results: The meta-analysis involved 6 case-control studies with a total of 371 cases and 269 controls. Pooled SMD showed no significant difference in serum Omentin between NAFLD and healthy groups (SMD= -0.047 and 95% CI -0.957_0.862 P=0.91). Subgroup analysis based on sample size showed that the average Omentin levels were significantly higher in NAFLD patients in studies with sample size ≥70 (SMD=0.356 CI 0.056_0.655 P=0.02).

Conclusion: Additional well-designed studies with more sample sizes are essential to clarify the potential role of Omentin as a risk marker of NAFLD

« Previous Next »
[1]
Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018; 3(7): 509-17.
[http://dx.doi.org/10.1016/S2468-1253(18)30077-3] [PMID: 29893235]
[2]
Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (Suppl. 1): S4-8.
[3]
Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22(9): 1129-33.
[http://dx.doi.org/10.1111/j.1464-5491.2005.01748.x] [PMID: 16108837]
[4]
Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review. Obes Rev 2016; 17(1): 68-80.
[http://dx.doi.org/10.1111/obr.12333] [PMID: 26597657]
[5]
Bessone F. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 2019; 76(1): 99-128.
[http://dx.doi.org/10.1007/s00018-018-2947-0]
[6]
Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation 2019; 103(1): e1-e13.
[http://dx.doi.org/10.1097/TP.0000000000002480] [PMID: 30300287]
[7]
Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014; 220(2): T47-59.
[http://dx.doi.org/10.1530/JOE-13-0339] [PMID: 24403378]
[8]
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11(2): 85-97.
[http://dx.doi.org/10.1038/nri2921] [PMID: 21252989]
[9]
Schäffler A, Schölmerich J, Büchler C. Mechanisms of Disease: Adipocytokines and visceral adipose tissue—emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2(6): 273-80.
[http://dx.doi.org/10.1038/ncpgasthep0186] [PMID: 16265231]
[10]
Jung UJ, Choi M. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15(4): 6184-223.
[http://dx.doi.org/10.3390/ijms15046184]
[11]
Ferns GA. A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease. Arch Physiol Biochem 2021; 2021: 1-7.
[12]
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1062-79.
[http://dx.doi.org/10.1016/j.metabol.2015.11.006] [PMID: 26725002]
[13]
Jaikanth C. 2013; Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes 2013; 121(7): 377-83.
[http://dx.doi.org/10.1055/s-0033-1345123]
[14]
Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2012; 71(1): 181-9.
[http://dx.doi.org/10.1017/S002966511100320X] [PMID: 22051112]
[15]
Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290(6): E1253-61.
[http://dx.doi.org/10.1152/ajpendo.00572.2004] [PMID: 16531507]
[16]
Ansari MHK, Gholamnejad M, Meghrazi K, Khalkhali HR. Association of circulating omentin-1 level with lung cancer in smokers. Med J Islam Repub Iran 2018; 32: 133.
[PMID: 30815428]
[17]
Halabis M, Dziedzic M, Warchulinska J, Kaznowska-Bystryk I, Solski J. Omentin - a new adipokine with many roles to play. Curr Issues Pharm Med Sci 2015; 28(3): 176-80.
[http://dx.doi.org/10.1515/cipms-2015-0067]
[18]
Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408(2): 339-43.
[http://dx.doi.org/10.1016/j.bbrc.2011.04.039] [PMID: 21514279]
[19]
Chai B, Zheng ZH, Liao X, et al. The protective role of omentin-1 in IL-1β-induced chondrocyte senescence. Artif Cells Nanomed Biotechnol 2020; 48(1): 8-14.
[http://dx.doi.org/10.1080/21691401.2019.1699803] [PMID: 31852248]
[20]
Zhong X, Li X, Liu F, Tan H, Shang D. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun 2012; 425(2): 401-6.
[http://dx.doi.org/10.1016/j.bbrc.2012.07.110] [PMID: 22842465]
[21]
Saloki NK. The association of serum omentin-1 levels with biochemical parameters in patients with nonalcoholic fatty liver disease. Med Sci 2021; 31(1): 122-8.
[22]
Rashad N. The association of serum omentin-1 levels with severity of nonalcoholic fatty liver disease in correlation with cardiovascular risk factors among Egyptian women. Med J Cairo Univ 2019; 87(June): 1783-91.
[http://dx.doi.org/10.21608/mjcu.2019.53966]
[23]
Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 2011; 39(2): 91-2.
[http://dx.doi.org/10.1016/j.jcms.2010.11.001] [PMID: 21145753]
[24]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[25]
Montazerifar F. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci 2017; 22: 70.
[26]
Waluga M, Kukla M, Kotulski R, et al. Omentin, vaspin and irisin in chronic liver diseases. J Physiol Pharmacol 2019; 70(2): 277-85.
[PMID: 31443090]
[27]
Yilmaz Y, Yonal O, Kurt R, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46(1): 91-7.
[http://dx.doi.org/10.3109/00365521.2010.516452] [PMID: 20809771]
[28]
Bekaert M, Ouwens DM, Hörbelt T, et al. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity (Silver Spring) 2016; 24(12): 2544-52.
[http://dx.doi.org/10.1002/oby.21674] [PMID: 27768254]
[29]
Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012; 4(1): 37.
[http://dx.doi.org/10.1186/1758-5996-4-37] [PMID: 22835063]
[30]
Lis I, Pilarski Ł, Bogdański P. Omentin - a newly-discovered adipocytokine in insulin resistance pathogenesis. Pol Merkur Lekarski 2015; 39(229): 56-60.
[31]
Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010; 88(1): 29-33.
[http://dx.doi.org/10.1016/j.diabres.2010.01.013] [PMID: 20129687]
[32]
Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57(4): 801-8.
[http://dx.doi.org/10.2337/db07-0990] [PMID: 18174521]
[33]
Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011; 93(1): 21-5.
[http://dx.doi.org/10.1016/j.diabres.2011.03.001] [PMID: 21497934]
[34]
Waluga M. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease. J Physiol Pharmacol 2017; 68(3): 363-74.
[35]
Marra F. Modulation of liver fibrosis by adipokines. Dig Dis 2011; 29(4): 371-6.
[http://dx.doi.org/10.1159/000329799]
[36]
Kukla M. Potential Role of Leptin, Adiponectin and Three Novel Adipokines—Visfatin, Chemerin and Vaspin—in Chronic Hepatitis. Molecular Medicine 2011; 17: 1397-410.
[37]
Kukla M, Waluga M, Adamek B, et al. Omentin serum concentration and hepatic expression in chronic hepatitis C patients – together or apart? Pol J Pathol 2015; 3(3): 231-8.
[http://dx.doi.org/10.5114/pjp.2015.54956] [PMID: 26619101]
[38]
Kohan L, Safarpur M, Abdollahi HJMBRC. Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease. Mol Biol Res Commun 2016; 5(1): 11-7.
[39]
Yaykasli KO. The frequency of omentin Val109Asp polymorphism and the serum level of omentin in patients with rheumatoid arthritis. Acta Medica Mediterranea 2013; 29: 521.
[40]
Yörük Ü. Association of omentin Val109Asp polymorphism with coronary artery disease. Anadolu Kardiyol Derg 2014; 14(6): 511-4.
[http://dx.doi.org/10.5152/akd.2013.4932]
[41]
Stojsavljević S. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-91.
[http://dx.doi.org/10.3748/wjg.v20.i48.18070]
[42]
Kłusek-Oksiuta M. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children. Ital J Pediatr 2014; 40: 84.
[http://dx.doi.org/10.1186/s13052-014-0084-4]
[43]
Arjmand M-H. Clinical significance of circulating omentin levels in various malignant tumors: Evidence from a systematic review and meta-analysis. Cytokine 2020; 125: 154869.
[http://dx.doi.org/10.1016/j.cyto.2019.154869]
[44]
Moreno-Navarrete JM. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7: 27.
[http://dx.doi.org/10.1186/1743-7075-7-27]
[45]
Yin J. Decreased levels of serum omentin-1 in patients with inflammatory bowel disease. Med Sci Monit 2015; 421: 118-22.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy